Hereditary sideroblastic anaemia

D3_SIDEROANAEMIAHERED

anemia (phenotype): ['A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.']

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D64.0 Hospital discharge: ICD-9 — 2850A Cause of death: ICD-10 — D64.0 Cause of death: ICD-9 — 2850A 2 out of 7 registries used, show all original rules.	141
4. Check minimum number of events None	141
5. Include endpoints None	141
6. Filter based on genotype QC (FinnGen only)	134

Control definitions (FinnGen only)

Control exclude: D3_APLASTICANDOTHANAEMIA

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: D64
Name in latin: Anaemia sideroblastica hereditaria

NAME	D3_SIDEROANAEMIAHERED
CONTROL_EXCLUDE	D3_APLASTICANDOTHANAEMIA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D640
HD_ICD_9	2850A
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D640
COD_ICD_9	2850A
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Hereditary sideroblastic anaemia based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	1481	806	652
Only index persons	986	576	410
Unadjusted period prevalence (%)
Whole population	0.02	0.02	0.02
Only index persons	0.02	0.02	0.02
Median age at first event (years)
Whole population	74.92	76.56	72.85
Only index persons	72.92	75.87	68.78

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	134	65	69
Unadjusted period prevalence (%)	0.03	0.02	0.03
Median age at first event (years)	68.10	65.63	70.42

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
141: Matched controls
1410

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

D64.0

ICD-10 Finland

Hereditary sideroblastic anaemia

+∞

195.1

138

D64.9

ICD-10 Finland

Anaemia, unspecified

65.6

133.2

D50.9

ICD-10 Finland

Iron deficiency anaemia, unspecified

13.1

42.5

UJD10

NOMESCO Finland

Esophagoscopy, gastroscopy and duodenoscopy

5.8

24.3

255

UJF32

NOMESCO Finland

Coloscopy

4.9

19.5

219

D50.0

ICD-10 Finland

Iron deficiency anaemia secondary to blood loss (chronic)

12.9

13.7

K44.9

ICD-10 Finland

Diaphragmatic hernia without obstruction or gangrene

5.2

11.3

WW500

NOMESCO Finland

Blood transfusion

10.1

10.7

D50.8

ICD-10 Finland

Other iron deficiency anaemias

35.5

10.5

UJF92

NOMESCO Finland

Capsular endoscopy

35.5

10.5

C03CA01

ATC

furosemide; systemic

3.0

9.3

472

D64.8

ICD-10 Finland

Other specified anaemias

20.3

9.1

JN3AE

NOMESCO Finland

Abdominal ultrasound examination

3.6

8.3

107

XW000

NOMESCO Finland

Bone marrow biopsy

8.9

7.8

ZX120

NOMESCO Finland

Intravenous

3.6

7.8

UJD02

NOMESCO Finland

Gastroscopy

6.5

7.5

D46.0

ICD-10 Finland

Refractory anaemia without ring sideroblasts, so stated

84.3

7.5

K55.2

ICD-10 Finland

Angiodysplasia of colon

84.3

7.5

D46.9

ICD-10 Finland

Myelodysplastic syndrome, unspecified

31.8

7.2

B03BA03

ATC

hydroxocobalamin; parenteral

4.4

7.2

Z04.8

ICD-10 Finland

Examination and observation for other specified reasons

3.5

6.6

D64.3

ICD-10 Finland

Other sideroblastic anaemias

+∞

6.3

TPH04

NOMESCO Finland

Cathetrisation of vein

2.7

6.2

186

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Outpatient Visit
OP [9202]

8.4e-01

8.8e-01

1.2e+00

4.8e+00

1.7e+00

1.6e+00

cases:78.42%

controls:61.01%

cases:64.75%

controls:43.18%

cases:28.06%

controls:10.11%

cases:30.94%

controls:0.36%

cases:39.57%

controls:10.56%

cases:80.80%

controls:44.74%

cases:94.00%

controls:76.15%

109

845

540

598

787

140

100

1245

1380

146

1237

101

604

746

913

286

Internal Medicine
11 [38004456]

8.4e-01

1.4e+00

2.9e+00

1.0e+50

3.0e+00

2.0e+00

1.3e+00

cases:45.32%

controls:26.43%

cases:35.25%

controls:11.70%

cases:20.14%

controls:1.37%

cases:52.52%

controls:0.00%

cases:25.18%

controls:1.59%

cases:49.60%

controls:12.15%

cases:60.00%

controls:28.19%

366

1019

162

1223

111

1366

1385

104

1361

164

1186

338

861

Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]

2.1e+00

2.4e+00

—

1.0e+50

—

2.0e+00

1.7e+00

cases:17.27%

controls:2.60%

cases:8.63%

controls:0.87%

—

cases:13.67%

controls:0.00%

—

cases:10.40%

controls:1.48%

cases:19.00%

controls:4.00%

115

1349

127

1373

—

120

1385

—

112

1330

1151

Inpatient Hospital
21 [8717]

9.3e-01

1.2e+00

1.8e+00

—

2.5e+00

1.2e+00

4.5e-01

cases:61.15%

controls:38.41%

cases:41.73%

controls:17.98%

cases:15.83%

controls:3.10%

—

cases:25.90%

controls:2.89%

cases:43.20%

controls:18.30%

cases:50.00%

controls:38.87%

532

853

249

1136

117

1342

—

103

1343

247

1103

466

733

INR in Blood by Coagulation assay
34714-6 [3032080]

9.7e-01

1.3e+00

1.9e+00

1.0e+50

2.1e+00

1.1e+00

9.0e-01

cases:8.63%

controls:3.47%

cases:10.79%

controls:3.18%

cases:9.35%

controls:1.44%

cases:3.60%

controls:0.00%

cases:8.63%

controls:1.16%

cases:10.40%

controls:3.70%

cases:22.00%

controls:10.26%

127

1337

124

1341

126

1365

134

1385

127

1367

112

1300

123

1076

Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]

1.5e+00

2.0e+00

—

1.0e+50

2.3e+00

1.5e+00

cases:7.19%

controls:1.73%

cases:8.63%

controls:1.30%

—

cases:6.47%

controls:0.00%

cases:12.80%

controls:1.41%

cases:22.00%

controls:5.92%

129

1361

127

1367

—

130

1383

109

1331

1128

Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]

1.5e+00

2.4e+00

—

1.7e+00

1.6e+00

cases:6.47%

controls:1.52%

cases:10.07%

controls:1.01%

—

cases:7.20%

controls:1.41%

cases:19.00%

controls:4.59%

130

1364

125

1371

—

116

1331

1144

Outpatient Hospital
22 [8756]

7.9e-01

8.5e-01

1.6e+00

1.0e+50

2.6e+00

1.2e+00

3.8e-01

cases:45.32%

controls:27.29%

cases:23.02%

controls:11.34%

cases:6.47%

controls:1.44%

cases:20.86%

controls:0.00%

cases:11.51%

controls:0.94%

cases:29.60%

controls:10.81%

cases:38.00%

controls:29.44%

378

1007

157

107

1228

130

1365

110

1385

123

1370

146

1204

353

846

furosemide; oral, parenteral
C03CA01 [21601518]

1.2e+00

1.6e+00

9.8e-01

—

1.5e+00

1.4e+00

1.0e+00

cases:25.90%

controls:9.17%

cases:30.94%

controls:8.09%

cases:7.19%

controls:2.82%

—

cases:9.35%

controls:2.31%

cases:29.60%

controls:9.70%

cases:33.00%

controls:15.01%

127

103

1258

112

1273

129

1346

—

126

1351

131

1219

180

1019

Iron deficiency anaemia, unspecified
D50.9 [45605373]

—

3.3e+00

2.9e+00

—

cases:9.60%

controls:0.37%

cases:11.00%

controls:0.67%

—

113

1345

1191

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

5.7e-01

9.2e-01

2.7e+00

—

2.3e+00

1.1e+00

1.2e+00

cases:5.76%

controls:3.32%

cases:5.76%

controls:2.38%

cases:5.04%

controls:0.36%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.44%

cases:23.00%

controls:8.09%

131

1339

131

1352

132

1380

—

133

1377

116

1317

1102

General Practice
1 [38004446]

5.2e-01

9.8e-01

1.7e+00

—

2.5e+00

1.1e+00

5.4e-01

cases:23.74%

controls:15.67%

cases:19.42%

controls:8.30%

cases:6.47%

controls:1.30%

—

cases:15.11%

controls:1.45%

cases:24.80%

controls:9.93%

cases:36.00%

controls:24.60%

217

106

1168

115

112

1270

130

1367

—

118

1363

134

1216

295

904

Emergency Room Visit
ER [9203]

5.2e-01

9.5e-01

2.5e+00

1.0e+50

1.8e+00

8.4e-01

5.3e-01

cases:46.04%

controls:33.57%

cases:31.65%

controls:15.23%

cases:15.83%

controls:1.52%

cases:35.25%

controls:0.00%

cases:10.07%

controls:1.74%

cases:29.60%

controls:15.33%

cases:52.00%

controls:38.87%

465

920

211

1174

117

1364

1385

125

1359

207

1143

466

733

Upper gastrointestinal surgery
106 [44777669]

9.5e-01

1.4e+00

—

1.0e+50

2.2e+00

1.4e+00

7.4e-01

cases:17.27%

controls:7.44%

cases:9.35%

controls:2.60%

—

cases:3.60%

controls:0.00%

cases:5.76%

controls:0.65%

cases:12.00%

controls:3.19%

cases:18.00%

controls:9.51%

103

115

1282

126

1349

—

134

1385

131

1374

110

1307

114

1085

Laboratory Visit
OMOP4822461 [32036]

1.9e-01

2.9e-01

1.2e+00

3.1e+00

1.3e+00

1.5e-01

-1.2e-03

cases:17.99%

controls:15.31%

cases:20.14%

controls:15.88%

cases:17.99%

controls:5.99%

cases:8.63%

controls:0.43%

cases:16.55%

controls:4.99%

cases:20.80%

controls:18.37%

cases:32.00%

controls:32.03%

212

114

1173

220

111

1165

114

1302

127

1379

116

1314

248

1102

384

815

Coloscopy
UJF32 [2001305029]

1.4e+00

1.9e+00

—

1.0e+50

—

2.2e+00

7.3e-01

cases:13.67%

controls:3.61%

cases:5.76%

controls:0.87%

—

cases:5.04%

controls:0.00%

—

cases:7.20%

controls:0.81%

cases:7.00%

controls:3.50%

120

1335

131

1373

—

132

1385

—

116

1339

1157

General Surgery
2 [38004447]

9.0e-01

9.8e-01

1.3e+00

1.0e+50

1.9e+00

1.2e+00

3.2e-01

cases:43.88%

controls:24.19%

cases:19.42%

controls:8.30%

cases:5.04%

controls:1.37%

cases:13.67%

controls:0.00%

cases:5.76%

controls:0.94%

cases:24.00%

controls:8.96%

cases:28.00%

controls:22.02%

335

1050

115

112

1270

132

1366

120

1385

131

1370

121

1229

264

935

Hematology
82 [38004501]

1.4e+00

1.8e+00

—

2.2e+00

2.6e+00

cases:3.60%

controls:0.94%

cases:4.32%

controls:0.72%

—

cases:7.20%

controls:0.81%

cases:11.00%

controls:0.92%

134

1372

133

1375

—

116

1339

1188

esomeprazole; oral, parenteral
A02BC05 [21600100]

1.1e+00

1.6e+00

—

2.2e+00

1.4e+00

8.0e-01

cases:17.99%

controls:6.79%

cases:9.35%

controls:3.39%

cases:4.32%

controls:0.94%

—

cases:6.47%

controls:0.72%

cases:16.00%

controls:4.30%

cases:18.00%

controls:9.01%

114

1291

126

1338

133

1372

—

130

1373

105

1292

108

1091

pantoprazole; oral, parenteral
A02BC02 [21600097]

7.9e-01

7.6e-01

8.7e-01

—

1.8e+00

1.3e+00

8.5e-01

cases:26.62%

controls:14.15%

cases:15.83%

controls:8.09%

cases:5.04%

controls:2.17%

—

cases:10.79%

controls:2.02%

cases:26.40%

controls:9.04%

cases:36.00%

controls:19.43%

196

102

1189

112

117

1273

132

1355

—

124

1355

122

1228

233

966

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

9.5e-01

1.2e+00

—

1.5e+00

1.0e+00

cases:13.67%

controls:5.78%

cases:10.07%

controls:3.39%

—

cases:9.60%

controls:2.37%

cases:18.00%

controls:7.42%

120

1305

125

1338

—

113

1318

1110

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

5.8e-01

2.3e+00

—

2.2e+00

5.0e-01

3.2e-01

cases:15.11%

controls:9.03%

cases:15.83%

controls:9.53%

cases:13.67%

controls:1.59%

—

cases:12.95%

controls:1.66%

cases:17.60%

controls:11.48%

cases:28.00%

controls:22.10%

125

118

1260

132

117

1253

120

1363

—

121

1360

155

103

1195

265

934

Gastroenterology
10 [38004455]

1.2e+00

1.7e+00

—

1.0e+50

—

2.6e+00

1.8e+00

cases:8.63%

controls:2.74%

cases:5.04%

controls:0.94%

—

cases:3.60%

controls:0.00%

—

cases:18.40%

controls:1.70%

cases:22.00%

controls:4.25%

127

1347

132

1372

—

134

1385

—

102

1327

1148

CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]

—

2.4e+00

2.0e+00

—

cases:4.80%

controls:0.44%

cases:15.00%

controls:2.42%

—

119

1344

1170

Endocrinology
46 [38004485]

1.5e+00

1.1e+00

—

2.3e+00

2.0e+00

cases:5.76%

controls:1.37%

cases:3.60%

controls:1.23%

—

cases:7.20%

controls:0.74%

cases:14.00%

controls:2.17%

131

1366

134

1368

—

116

1340

1173

Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]

—

2.4e+00

1.9e+00

—

cases:4.80%

controls:0.44%

cases:12.00%

controls:2.00%

—

119

1344

1175

paracetamol; oral, parenteral, rectal
N02BE01 [21604344]

7.6e-01

8.6e-01

1.6e+00

—

8.1e-01

1.0e+00

4.0e-01

cases:38.13%

controls:22.38%

cases:28.78%

controls:14.66%

cases:13.67%

controls:3.10%

—

cases:8.63%

controls:4.05%

cases:35.20%

controls:16.22%

cases:48.00%

controls:38.12%

310

1075

203

1182

120

1342

—

127

1327

219

1131

457

742

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

1.7e-01

6.2e-01

2.2e+00

—

2.1e+00

7.0e-01

4.2e-01

cases:7.19%

controls:6.14%

cases:12.23%

controls:7.00%

cases:12.23%

controls:1.59%

—

cases:10.07%

controls:1.37%

cases:16.00%

controls:8.67%

cases:27.00%

controls:19.52%

129

1300

122

1288

122

1363

—

125

1364

117

105

1233

234

965

Type 2 diabetes mellitus, without complications
E11.9 [45561952]

1.3e+00

1.4e+00

—

1.1e+00

1.5e+00

cases:15.11%

controls:4.62%

cases:8.63%

controls:2.24%

—

cases:8.00%

controls:2.89%

cases:26.00%

controls:7.59%

118

1321

127

1354

—

115

1311

1108

Specific gravity of Urine by Refractometry
5810-7 [3019150]

9.4e-01

1.5e+00

—

2.8e+00

1.2e+00

1.3e+00

cases:4.32%

controls:1.73%

cases:6.47%

controls:1.59%

—

cases:5.76%

controls:0.36%

cases:6.40%

controls:2.00%

cases:17.00%

controls:5.34%

133

1361

130

1363

—

131

1378

117

1323

1135

allopurinol; oral, parenteral
M04AA01 [21604131]

1.2e+00

1.6e+00

—

1.2e+00

cases:12.23%

controls:3.90%

cases:12.23%

controls:2.67%

—

cases:9.60%

controls:2.96%

cases:12.00%

controls:4.09%

122

1331

122

1348

—

113

1310

1150

Basophils [#/volume] in Blood
26444-0 [3006315]

6.9e-01

1.0e+00

2.3e+00

—

2.5e+00

1.1e+00

1.5e+00

cases:5.04%

controls:2.60%

cases:5.04%

controls:1.88%

cases:3.60%

controls:0.36%

—

cases:4.32%

controls:0.36%

cases:7.20%

controls:2.59%

cases:24.00%

controls:6.67%

132

1349

132

1359

134

1380

—

133

1378

116

1315

1119

Monocytes [#/volume] in Blood
26484-6 [3001604]

7.2e-01

1.1e+00

2.3e+00

—

2.5e+00

1.1e+00

1.5e+00

cases:5.04%

controls:2.53%

cases:5.04%

controls:1.81%

cases:3.60%

controls:0.36%

—

cases:4.32%

controls:0.36%

cases:7.20%

controls:2.59%

cases:24.00%

controls:6.67%

132

1350

132

1360

134

1380

—

133

1378

116

1315

1119

Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]

6.7e-01

9.6e-01

—

2.8e+00

9.5e-01

1.1e+00

cases:5.76%

controls:3.03%

cases:7.19%

controls:2.89%

—

cases:6.47%

controls:0.43%

cases:8.00%

controls:3.26%

cases:21.00%

controls:8.26%

131

1343

129

1345

—

130

1377

115

1306

1100

pH of Urine by Test strip
5803-2 [3022621]

—

2.2e+00

—

1.6e+00

—

cases:5.04%

controls:0.58%

—

cases:9.00%

controls:1.92%

—

132

1377

—

1176

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

5.3e-01

9.4e-01

2.3e+00

—

2.3e+00

9.8e-01

1.4e+00

cases:5.04%

controls:3.03%

cases:5.04%

controls:2.02%

cases:3.60%

controls:0.36%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.81%

cases:24.00%

controls:7.01%

132

1343

132

1357

134

1380

—

133

1377

116

1312

1115

Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]

7.0e-01

8.1e-01

—

2.9e+00

8.8e-01

8.9e-01

cases:6.47%

controls:3.32%

cases:7.19%

controls:3.32%

—

cases:7.19%

controls:0.43%

cases:8.00%

controls:3.48%

cases:21.00%

controls:9.84%

130

1339

129

1339

—

129

1377

115

1303

118

1081

Ketones [Presence] in Urine by Test strip
2514-8 [3035350]

7.0e-01

9.1e-01

—

2.9e+00

9.0e-01

8.9e-01

cases:6.47%

controls:3.32%

cases:7.19%

controls:3.03%

—

cases:7.19%

controls:0.43%

cases:8.00%

controls:3.41%

cases:21.00%

controls:9.84%

130

1339

129

1343

—

129

1377

115

1304

118

1081

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

2.6e-01

3.6e-01

1.9e+00

—

1.8e+00

2.6e-01

1.1e-01

cases:16.55%

controls:13.21%

cases:18.71%

controls:13.86%

cases:16.55%

controls:2.74%

—

cases:13.67%

controls:2.53%

cases:20.00%

controls:16.15%

cases:32.00%

controls:29.69%

183

116

1202

192

113

1193

116

1347

—

120

1348

218

100

1132

356

843

Monocytes/Leukocytes in Blood
26485-3 [3019069]

5.8e-01

1.1e+00

2.1e+00

—

2.3e+00

1.0e+00

1.4e+00

cases:5.04%

controls:2.89%

cases:5.04%

controls:1.81%

cases:3.60%

controls:0.43%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.67%

cases:21.00%

controls:6.17%

132

1345

132

1360

134

1379

—

133

1377

116

1314

1125

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

4.4e-01

1.0e+00

2.0e+00

—

2.3e+00

9.3e-01

1.4e+00

cases:4.32%

controls:2.82%

cases:5.04%

controls:1.88%

cases:3.60%

controls:0.51%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.96%

cases:21.00%

controls:6.26%

133

1346

132

1359

134

1378

—

133

1377

116

1310

1124

Basophils/Leukocytes in Blood
30180-4 [3022096]

5.8e-01

1.1e+00

2.1e+00

—

2.3e+00

1.1e+00

1.4e+00

cases:5.04%

controls:2.89%

cases:5.04%

controls:1.81%

cases:3.60%

controls:0.43%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.59%

cases:21.00%

controls:6.26%

132

1345

132

1360

134

1379

—

133

1377

116

1315

1124

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

5.8e-01

1.1e+00

2.1e+00

—

2.3e+00

1.1e+00

1.4e+00

cases:5.04%

controls:2.89%

cases:5.04%

controls:1.81%

cases:3.60%

controls:0.43%

—

cases:4.32%

controls:0.43%

cases:7.20%

controls:2.59%

cases:21.00%

controls:6.26%

132

1345

132

1360

134

1379

—

133

1377

116

1315

1124

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

3.2e-01

3.5e-01

1.9e+00

—

1.8e+00

2.6e-01

1.1e-01

cases:17.27%

controls:13.14%

cases:18.71%

controls:13.94%

cases:15.83%

controls:2.74%

—

cases:14.39%

controls:2.68%

cases:20.00%

controls:16.15%

cases:32.00%

controls:29.69%

182

115

1203

193

113

1192

117

1347

—

119

1346

218

100

1132

356

843

Leukocytes [#/volume] in Blood
26464-8 [3010813]

2.6e-01

3.5e-01

1.9e+00

—

1.8e+00

3.1e-01

1.1e-01

cases:16.55%

controls:13.21%

cases:18.71%

controls:13.94%

cases:15.83%

controls:2.74%

—

cases:13.67%

controls:2.53%

cases:20.80%

controls:16.15%

cases:32.00%

controls:29.69%

183

116

1202

193

113

1192

117

1347

—

120

1348

218

1132

356

843

MCH [Entitic mass]
28539-5 [3035941]

2.7e-01

3.6e-01

1.9e+00

—

1.8e+00

2.6e-01

1.1e-01

cases:16.55%

controls:13.14%

cases:18.71%

controls:13.86%

cases:15.83%

controls:2.74%

—

cases:13.67%

controls:2.53%

cases:20.00%

controls:16.15%

cases:32.00%

controls:29.69%

182

116

1203

192

113

1193

117

1347

—

120

1348

218

100

1132

356

843

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

2.7e-01

3.5e-01

1.9e+00

—

1.8e+00

2.6e-01

1.1e-01

cases:16.55%

controls:13.14%

cases:18.71%

controls:13.94%

cases:15.83%

controls:2.74%

—

cases:13.67%

controls:2.60%

cases:20.00%

controls:16.15%

cases:32.00%

controls:29.69%

182

116

1203

193

113

1192

117

1347

—

120

1347

218

100

1132

356

843

Platelets [#/volume] in Blood
26515-7 [3007461]

2.7e-01

3.5e-01

1.9e+00

—

1.8e+00

2.2e-01

1.1e-01

cases:16.55%

controls:13.14%

cases:18.71%

controls:13.94%

cases:15.83%

controls:2.74%

—

cases:13.67%

controls:2.60%

cases:19.20%

controls:16.00%

cases:32.00%

controls:29.69%

182

116

1203

193

113

1192

117

1347

—

120

1347

216

101

1134

356

843

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

2.7e-01

3.5e-01

1.9e+00

—

1.8e+00

2.6e-01

1.1e-01

cases:16.55%

controls:13.14%

cases:18.71%

controls:13.94%

cases:15.83%

controls:2.74%

—

cases:13.67%

controls:2.60%

cases:20.00%

controls:16.15%

cases:32.00%

controls:29.69%

182

116

1203

193

113

1192

117

1347

—

120

1347

218

100

1132

356

843

Anaemia, unspecified
D64.9 [45600610]

—

1.0e+50

3.6e+00

—

cases:12.95%

controls:0.00%

cases:7.91%

controls:0.00%

cases:10.07%

controls:0.00%

cases:20.80%

controls:0.00%

cases:18.00%

controls:0.58%

—

121

1385

128

1385

125

1383

1350

1192

Eosinophils [#/volume] in Blood
26449-9 [3013115]

6.0e-01

9.4e-01

2.0e+00

—

2.2e+00

9.8e-01

1.4e+00

cases:5.04%

controls:2.82%

cases:5.04%

controls:2.02%

cases:3.60%

controls:0.51%

—

cases:4.32%

controls:0.51%

cases:7.20%

controls:2.81%

cases:23.00%

controls:6.84%

132

1346

132

1357

134

1378

—

133

1376

116

1312

1117

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

4.8e-01

9.4e-01

2.1e+00

—

2.2e+00

9.8e-01

1.3e+00

cases:5.04%

controls:3.18%

cases:5.04%

controls:2.02%

cases:3.60%

controls:0.43%

—

cases:4.32%

controls:0.51%

cases:7.20%

controls:2.81%

cases:21.00%

controls:6.51%

132

1341

132

1357

134

1379

—

133

1376

116

1312

1121

Office Visit
OMOP4822458 [581477]

7.6e-01

1.4e+00

—

1.9e+00

7.9e-01

cases:18.71%

controls:9.68%

cases:12.95%

controls:3.47%

—

cases:18.40%

controls:3.11%

cases:23.00%

controls:11.93%

134

113

1251

121

1337

—

102

1308

143

1056

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

2.5e-01

4.9e-01

1.6e+00

—

1.6e+00

3.0e-01

1.5e-01

cases:15.11%

controls:12.13%

cases:18.71%

controls:12.35%

cases:11.51%

controls:2.45%

—

cases:8.63%

controls:1.81%

cases:18.40%

controls:14.37%

cases:31.00%

controls:27.94%

168

118

1217

171

113

1214

123

1351

—

127

1358

194

102

1156

335

864

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

2.7e-01

5.1e-01

1.7e+00

—

1.6e+00

3.2e-01

1.6e-01

cases:15.11%

controls:11.99%

cases:18.71%

controls:12.13%

cases:11.51%

controls:2.38%

—

cases:8.63%

controls:1.88%

cases:18.40%

controls:14.07%

cases:31.00%

controls:27.69%

166

118

1219

168

113

1217

123

1352

—

127

1357

190

102

1160

332

867

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

1.8e-01

6.0e-01

1.5e+00

—

1.7e+00

5.0e-01

3.6e-01

cases:11.51%

controls:9.82%

cases:14.39%

controls:8.45%

cases:7.91%

controls:1.81%

—

cases:7.19%

controls:1.45%

cases:14.40%

controls:9.26%

cases:31.00%

controls:23.85%

136

123

1249

117

119

1268

128

1360

—

129

1363

125

107

1225

286

913

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

2.0e-01

4.3e-01

1.6e+00

—

1.5e+00

2.5e-01

1.1e-01

cases:15.11%

controls:12.71%

cases:19.42%

controls:13.57%

cases:12.95%

controls:2.96%

—

cases:9.35%

controls:2.31%

cases:19.20%

controls:15.63%

cases:31.00%

controls:28.77%

176

118

1209

188

112

1197

121

1344

—

126

1351

211

101

1139

345

854

Iron deficiency anaemia secondary to blood loss (chronic)
D50.0 [45566697]

—

2.9e+00

—

cases:7.00%

controls:0.42%

—

1194

Glucose [Presence] in Urine by Test strip
25428-4 [3009261]

6.6e-01

7.9e-01

—

2.9e+00

8.2e-01

8.5e-01

cases:6.47%

controls:3.47%

cases:7.19%

controls:3.39%

—

cases:7.19%

controls:0.43%

cases:8.00%

controls:3.70%

cases:21.00%

controls:10.18%

130

1337

129

1338

—

129

1377

115

1300

122

1077

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

—

2.7e+00

—

cases:8.00%

controls:0.58%

—

1192

lansoprazole; oral
A02BC03 [21600098]

1.1e+00

1.5e+00

—

1.4e+00

4.0e-01

cases:11.51%

controls:3.97%

cases:7.91%

controls:1.88%

—

cases:6.40%

controls:1.63%

cases:6.00%

controls:4.09%

123

1330

128

1359

—

117

1328

1150

Intravenous
ZX120 [2001311495]

—

2.2e+00

2.6e+00

—

cases:4.00%

controls:0.44%

cases:12.00%

controls:1.00%

—

120

1344

1187

C reactive protein [Mass/volume] in Capillary blood
48421-2 [3051387]

—

2.6e+00

—

cases:8.00%

controls:0.67%

—

1191

Potassium [Moles/volume] in Venous blood
39789-3 [3041354]

—

2.5e+00

—

cases:6.00%

controls:0.50%

—

1193

Chloride [Moles/volume] in Venous blood
41649-5 [3035285]

—

2.5e+00

—

cases:6.00%

controls:0.50%

—

1193

Calcium.ionized [Moles/volume] in Venous blood
41645-3 [3033705]

—

2.5e+00

—

cases:6.00%

controls:0.50%

—

1193

Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]

-1.3e-01

3.9e-01

—

2.5e+00

-9.6e-02

4.2e-01

cases:5.04%

controls:5.70%

cases:7.19%

controls:4.98%

—

cases:6.47%

controls:0.58%

cases:4.80%

controls:5.26%

cases:21.00%

controls:14.85%

132

1306

129

1316

—

130

1375

119

1279

178

1021

Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]

1.2e+00

2.4e+00

—

1.2e+00

1.0e+00

cases:6.47%

controls:2.09%

cases:7.91%

controls:0.79%

—

cases:4.00%

controls:1.26%

cases:12.00%

controls:4.67%

130

1356

128

1374

—

120

1333

1143

Ileoscopy through colon
UJF30 [2001305028]

-1.0e+50

—

2.3e+00

cases:0.00%

controls:0.43%

—

cases:5.00%

controls:0.50%

139

1379

—

1193

Predominantly allergic asthma
J45.0 [45557624]

—

2.3e+00

—

cases:5.00%

controls:0.50%

—

1193

IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]

—

2.3e+00

—

cases:5.00%

controls:0.50%

—

1193

Atrial fibrillation and atrial flutter, unspecified
I48.9 [45755409]

—

2.3e+00

—

cases:5.00%

controls:0.50%

—

1193

Examination and observation for other specified reasons
Z04.8 [45552063]

2.3e+00

—

cases:5.04%

controls:0.51%

—

132

1378

—

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

7.9e-01

9.6e-01

2.3e+00

—

9.1e-01

6.1e-01

cases:12.23%

controls:5.92%

cases:11.51%

controls:4.77%

cases:4.32%

controls:0.43%

—

cases:12.00%

controls:5.19%

cases:24.00%

controls:14.68%

122

1303

123

1319

133

1379

—

110

1280

176

1023

Glucose [Moles/volume] in Venous blood
39480-9 [3038515]

—

2.3e+00

—

cases:8.00%

controls:0.83%

—

1189

enalapril; oral, parenteral
C09AA02 [21601786]

7.9e-01

9.8e-01

—

1.3e+00

1.1e+00

1.2e+00

cases:12.23%

controls:5.92%

cases:10.79%

controls:4.33%

—

cases:4.32%

controls:1.23%

cases:11.20%

controls:4.07%

cases:15.00%

controls:5.00%

122

1303

124

1325

—

133

1366

111

1295

1139

Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]

—

2.3e+00

—

cases:7.00%

controls:0.75%

—

1190

enoxaparin; parenteral
B01AB05 [21600976]

1.3e+00

1.4e+00

—

2.3e+00

4.7e-01

cases:7.19%

controls:2.17%

cases:3.60%

controls:0.94%

—

cases:8.00%

controls:0.89%

cases:7.00%

controls:4.50%

129

1355

134

1372

—

115

1338

1145

Case Management Agency
251B00000X [38004193]

3.5e-01

1.8e-01

7.4e-01

2.3e+00

5.8e-01

3.7e-01

2.4e-01

cases:46.04%

controls:37.47%

cases:35.97%

controls:31.91%

cases:18.71%

controls:9.89%

cases:6.47%

controls:0.72%

cases:16.55%

controls:9.98%

cases:42.40%

controls:33.70%

cases:66.00%

controls:60.47%

519

866

442

943

137

113

1248

130

1375

138

116

1245

455

895

725

474

Lactate [Moles/volume] in Venous blood
2519-7 [3008037]

—

2.2e+00

—

cases:8.00%

controls:0.92%

—

1188

Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]

1.7e+00

—

2.2e+00

cases:3.60%

controls:0.65%

—

cases:10.00%

controls:1.25%

134

1376

—

1184

Extensive body CT
JN4BD [2001310899]

-1.0e+50

—

2.1e+00

cases:0.00%

controls:0.79%

—

cases:6.00%

controls:0.75%

139

1374

—

1190

Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]

—

2.1e+00

—

cases:8.00%

controls:1.08%

—

1186

Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]

—

2.1e+00

—

cases:8.00%

controls:1.08%

—

1186

hydroxychloroquine; oral
P01BA02 [21604889]

2.0e+00

—

cases:4.32%

controls:0.58%

—

133

1377

—

lidocaine, combinations
N01BB52 [21604241]

2.0e+00

—

cases:4.32%

controls:0.58%

—

133

1377

—

calcium (different salts in combination); oral
A12AA20 [21600872]

3.0e-01

6.4e-01

—

1.0e+00

9.4e-01

1.1e+00

cases:12.23%

controls:9.39%

cases:13.67%

controls:7.73%

—

cases:5.76%

controls:2.17%

cases:18.40%

controls:8.07%

cases:30.00%

controls:12.59%

130

122

1255

107

120

1278

—

131

1353

109

102

1241

151

1048

Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]

—

2.0e+00

—

cases:7.00%

controls:1.00%

—

1187

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

2.5e-01

1.0e+00

1.3e+00

—

1.7e+00

1.0e+00

7.9e-01

cases:8.63%

controls:6.86%

cases:11.51%

controls:4.55%

cases:3.60%

controls:1.01%

—

cases:3.60%

controls:0.65%

cases:13.60%

controls:5.48%

cases:25.00%

controls:13.18%

127

1290

123

1322

134

1371

—

134

1374

108

1276

158

1041

Bacteria [#/volume] in Urine by Culture
100906-7 [1761482]

—

2.0e+00

—

cases:10.00%

controls:1.50%

—

1181

Specific gravity of Urine by Test strip
5811-5 [3000330]

—

1.9e+00

—

cases:10.00%

controls:1.58%

—

1180

Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]

—

1.9e+00

—

cases:7.00%

controls:1.08%

—

1186

Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]

—

2.0e+00

—

2.1e+00

1.9e+00

—

cases:3.60%

controls:0.51%

—

cases:4.00%

controls:0.52%

cases:12.00%

controls:2.00%

—

134

1378

—

120

1343

1175

metformin; oral
A10BA02 [21600747]

9.9e-01

9.0e-01

9.1e-01

—

3.9e-01

7.0e-01

6.9e-01

cases:21.58%

controls:9.31%

cases:17.27%

controls:7.80%

cases:5.04%

controls:2.09%

—

cases:3.60%

controls:2.46%

cases:15.20%

controls:8.15%

cases:19.00%

controls:10.51%

129

109

1256

108

115

1277

132

1356

—

134

1349

110

106

1240

126

1073

Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]

—

1.9e+00

—

cases:8.00%

controls:1.33%

—

1183

Rheumatology
66 [38004491]

1.8e+00

1.6e+00

—

1.3e+00

9.8e-01

cases:6.47%

controls:1.08%

cases:3.60%

controls:0.72%

—

cases:4.00%

controls:1.11%

cases:7.00%

controls:2.75%

130

1370

134

1375

—

120

1335

1166

Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]

—

2.1e+00

1.8e+00

—

cases:4.00%

controls:0.52%

cases:10.00%

controls:1.83%

—

120

1343

1177

ferrous glycine sulfate; oral
B03AA01 [21601080]

—

1.8e+00

—

cases:7.00%

controls:1.25%

—

1184

Scheduled procedure
ZXD10 [2001311387]

8.5e-01

1.2e+00

—

1.8e+00

9.4e-01

cases:15.83%

controls:7.44%

cases:7.19%

controls:2.38%

—

cases:10.40%

controls:1.93%

cases:14.00%

controls:6.01%

103

117

1282

129

1352

—

112

1324

1127

Standard cardiac ultrasound examination
FM1AE [2001303278]

9.5e-01

—

1.7e+00

cases:5.76%

controls:2.31%

—

cases:13.00%

controls:2.59%

131

1353

—

1168

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

1.7e+00

—

1.5e+00

1.1e+00

cases:5.76%

controls:1.08%

—

cases:4.00%

controls:0.89%

cases:11.00%

controls:4.00%

131

1370

—

120

1338

1151

CBC panel - Blood by Automated count
58410-2 [40761511]

-7.4e-02

1.6e-01

1.3e+00

—

1.7e+00

2.9e-01

3.0e-01

cases:10.07%

controls:10.76%

cases:11.51%

controls:9.96%

cases:6.47%

controls:1.81%

—

cases:7.91%

controls:1.52%

cases:15.20%

controls:11.85%

cases:30.00%

controls:24.19%

149

125

1236

138

123

1247

130

1360

—

128

1362

160

106

1190

290

909

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

1.9e-01

5.1e-01

1.7e+00

—

1.1e+00

3.6e-01

2.0e-01

cases:12.95%

controls:10.97%

cases:15.83%

controls:10.18%

cases:6.47%

controls:1.23%

—

cases:3.60%

controls:1.23%

cases:16.80%

controls:12.37%

cases:29.00%

controls:25.10%

152

121

1233

141

117

1244

130

1368

—

134

1366

167

104

1183

301

898

Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]

-1.0e+50

—

1.7e+00

cases:0.00%

controls:0.36%

—

cases:9.00%

controls:1.83%

139

1380

—

1177

Base excess in Venous blood by calculation
1927-3 [3002032]

-1.0e+50

—

1.7e+00

cases:0.00%

controls:0.43%

—

cases:9.00%

controls:1.83%

139

1379

—

1177

pH of Venous blood
2746-6 [3012544]

-1.0e+50

—

1.7e+00

cases:0.00%

controls:0.43%

—

cases:9.00%

controls:1.83%

139

1379

—

1177

Need for immunization against other specified single viral diseases
Z25.8 [45547296]

—

1.7e+00

—

cases:9.00%

controls:1.83%

—

1177

Pneumonia, unspecified
J18.9 [45601123]

8.9e-01

1.7e+00

—

1.3e+00

6.1e-01

cases:5.76%

controls:2.45%

cases:5.76%

controls:1.16%

—

cases:8.00%

controls:2.37%

cases:12.00%

controls:6.92%

131

1351

131

1369

—

115

1318

1116

Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]

—

1.7e+00

—

8.6e-01

—

cases:5.76%

controls:1.16%

—

cases:10.00%

controls:4.50%

—

131

1369

—

1145

Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]

—

1.6e+00

—

cases:8.00%

controls:1.67%

—

1179

Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]

-1.0e+50

—

1.6e+00

cases:0.00%

controls:0.43%

—

cases:9.00%

controls:1.92%

139

1379

—

1176

Cathetrisation of vein
TPH04 [2001309597]

1.1e+00

—

1.8e+00

1.5e+00

cases:3.60%

controls:1.23%

—

cases:4.80%

controls:0.81%

cases:14.00%

controls:3.34%

134

1368

—

119

1339

1159

Atherosclerosis of arteries of extremities
I70.2 [45538421]

1.1e+00

1.6e+00

—

1.5e+00

cases:5.76%

controls:2.02%

cases:4.32%

controls:0.94%

—

cases:13.00%

controls:3.09%

131

1357

133

1372

—

1162

clindamycin; oral, parenteral
J01FF01 [21602985]

7.7e-01

—

1.5e+00

cases:6.47%

controls:3.10%

—

cases:12.00%

controls:2.92%

130

1342

—

1164

More than one and less than three hours
ZXE10 [2001311401]

7.4e-01

—

1.4e+00

1.5e+00

cases:8.63%

controls:4.33%

—

cases:5.60%

controls:1.41%

cases:17.00%

controls:4.50%

127

1325

—

118

1331

1145

Vascular Surgery
77 [38004496]

—

1.5e+00

1.4e+00

—

cases:4.80%

controls:1.11%

cases:13.00%

controls:3.42%

—

119

1335

1158

Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]

1.3e+00

1.4e+00

—

8.7e-01

6.5e-01

cases:7.19%

controls:2.09%

cases:7.19%

controls:1.81%

—

cases:4.80%

controls:2.07%

cases:12.00%

controls:6.67%

129

1356

129

1360

—

119

1322

1119

Uroflowmetry
44856007 [4261340]

—

-1.0e+50

1.4e+00

—

cases:0.00%

controls:1.19%

cases:10.00%

controls:2.59%

—

125

1334

1168

Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]

5.5e-01

1.4e+00

—

6.9e-01

8.1e-01

cases:4.32%

controls:2.53%

cases:7.19%

controls:1.88%

—

cases:5.60%

controls:2.89%

cases:18.00%

controls:8.92%

133

1350

129

1359

—

118

1311

107

1092

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]

5.5e-01

1.4e+00

—

7.1e-01

1.0e-02

cases:5.76%

controls:3.39%

cases:7.91%

controls:2.09%

—

cases:4.00%

controls:2.00%

cases:8.00%

controls:7.92%

131

1338

128

1356

—

120

1323

1104

Medical doctor
Z2221 [2001311556]

-2.9e-01

9.1e-01

—

1.5e+00

1.4e+00

cases:3.60%

controls:4.77%

cases:5.04%

controls:2.09%

—

cases:7.20%

controls:1.78%

cases:17.00%

controls:4.92%

134

1319

132

1356

—

116

1326

1140

Protein [Presence] in Urine by Test strip
20454-5 [3014051]

1.2e+00

—

1.3e+00

1.4e+00

cases:4.32%

controls:1.30%

cases:5.04%

controls:1.52%

—

cases:4.80%

controls:1.41%

cases:16.00%

controls:4.67%

133

1367

132

1364

—

119

1331

1143

enalapril and diuretics
C09BA02 [21601804]

1.4e+00

6.3e-01

—

-1.0e+50

—

8.1e-01

cases:7.91%

controls:2.17%

cases:3.60%

controls:1.95%

—

cases:0.00%

controls:0.58%

—

cases:6.00%

controls:2.75%

128

1355

134

1358

—

139

1375

—

1166

insulin glargine; parenteral
A10AE04 [21600739]

8.4e-01

7.1e-01

—

1.3e+00

cases:3.60%

controls:1.59%

cases:3.60%

controls:1.81%

—

cases:8.00%

controls:2.30%

cases:13.00%

controls:3.75%

134

1363

134

1360

—

115

1319

1154

insulin (beef); parenteral
A10AD02 [21600730]

8.4e-01

7.1e-01

—

1.3e+00

cases:3.60%

controls:1.59%

cases:3.60%

controls:1.81%

—

cases:8.00%

controls:2.30%

cases:13.00%

controls:3.75%

134

1363

134

1360

—

115

1319

1154

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

9.7e-01

1.3e+00

—

1.1e+00

7.3e-01

cases:8.63%

controls:3.47%

cases:9.35%

controls:2.67%

—

cases:9.60%

controls:3.56%

cases:19.00%

controls:10.18%

127

1337

126

1348

—

113

1302

122

1077

Infiltration anesthesia
WX110 [2001310767]

1.2e-01

2.5e-01

-1.0e+50

—

1.3e+00

5.3e-01

cases:6.47%

controls:5.78%

cases:4.32%

controls:3.39%

cases:0.00%

controls:0.36%

—

cases:11.20%

controls:3.26%

cases:19.00%

controls:12.18%

130

1305

133

1338

139

1380

—

111

1306

146

1053

glimepiride; oral
A10BB12 [21600761]

1.3e+00

9.4e-01

—

cases:9.35%

controls:2.82%

cases:4.32%

controls:1.73%

—

126

1346

133

1361

—

Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]

9.8e-01

1.2e+00

—

1.0e+00

1.2e+00

cases:5.04%

controls:1.95%

cases:5.04%

controls:1.59%

—

cases:5.60%

controls:2.07%

cases:17.00%

controls:5.67%

132

1358

132

1363

—

118

1322

1131

Inpatient Visit
IP [9201]

7.2e-01

—

-1.0e+50

1.2e+00

cases:5.04%

controls:2.53%

—

cases:0.00%

controls:0.59%

cases:14.00%

controls:4.59%

132

1350

—

125

1342

1144

Type 2 diabetes mellitus
E11 [45571656]

1.2e+00

9.2e-01

—

-1.0e+50

—

4.3e-01

cases:13.67%

controls:4.48%

cases:7.91%

controls:3.32%

—

cases:0.00%

controls:0.36%

—

cases:10.00%

controls:6.76%

120

1323

128

1339

—

139

1378

—

1118

Right side
ZXA00 [2001311346]

5.7e-01

—

1.7e+00

1.2e+00

cases:7.91%

controls:4.62%

—

cases:4.80%

controls:0.89%

cases:13.00%

controls:4.42%

128

1321

—

119

1338

1146

Thorax X-ray examination
GD1AA [2001303617]

—

6.9e-01

1.2e+00

—

cases:5.60%

controls:2.89%

cases:21.00%

controls:7.67%

—

118

1311

1107

Pulmonary Disease
29 [38004472]

8.3e-01

1.1e+00

—

9.0e-01

4.0e-01

cases:15.11%

controls:7.22%

cases:10.79%

controls:3.75%

—

cases:11.20%

controls:4.89%

cases:13.00%

controls:9.09%

100

118

1285

124

1333

—

111

1284

109

1090

Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]

1.2e+00

1.1e+00

—

1.1e+00

cases:6.47%

controls:2.02%

cases:5.76%

controls:1.95%

—

cases:4.80%

controls:1.70%

cases:18.00%

controls:6.84%

130

1357

131

1358

—

119

1327

1117

Urgent procedure
ZXD05 [2001311386]

3.9e-02

—

1.1e+00

cases:3.60%

controls:3.47%

—

cases:14.00%

controls:5.25%

134

1337

—

1136

codeine and paracetamol
N02AJ06 [1123647]

-3.3e-02

4.8e-01

—

1.1e+00

8.2e-01

cases:7.91%

controls:8.16%

cases:6.47%

controls:4.12%

—

cases:12.80%

controls:4.81%

cases:24.00%

controls:12.26%

113

128

1272

130

1328

—

109

1285

147

1052

Cardiology
6 [38004451]

6.2e-01

1.0e+00

—

7.1e-01

1.1e+00

cases:13.67%

controls:7.87%

cases:8.63%

controls:3.25%

—

cases:8.80%

controls:4.52%

cases:29.00%

controls:12.34%

109

120

1276

127

1340

—

114

1289

148

1051

One hour or less
ZXE00 [2001311394]

5.1e-01

7.9e-01

—

1.3e+00

1.0e+00

cases:7.91%

controls:4.91%

cases:3.60%

controls:1.66%

—

cases:7.20%

controls:2.00%

cases:16.00%

controls:6.26%

128

1317

134

1362

—

116

1323

1124

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

6.9e-01

1.4e+00

—

1.2e+00

1.0e+00

cases:5.76%

controls:2.96%

cases:7.19%

controls:1.95%

—

cases:7.20%

controls:2.30%

cases:17.00%

controls:6.84%

131

1344

129

1358

—

116

1319

1117

isosorbide mononitrate; oral
C01DA14 [21600324]

7.4e-01

7.5e-01

—

6.3e-01

1.0e+00

cases:14.39%

controls:7.44%

cases:11.51%

controls:5.78%

—

cases:3.60%

controls:1.95%

cases:11.20%

controls:6.30%

cases:21.00%

controls:8.76%

103

119

1282

123

1305

—

134

1356

111

1265

105

1094

bisoprolol; oral
C07AB07 [21601689]

5.8e-01

5.7e-01

4.7e-01

—

3.1e-01

5.4e-01

9.9e-01

cases:24.46%

controls:15.31%

cases:23.02%

controls:14.51%

cases:7.19%

controls:4.62%

—

cases:6.47%

controls:4.84%

cases:24.00%

controls:15.48%

cases:43.00%

controls:21.85%

212

105

1173

201

107

1184

129

1321

—

130

1316

209

1141

262

937

pH of Urine
2756-5 [3015736]

3.3e-01

9.2e-01

—

7.4e-01

9.8e-01

cases:3.60%

controls:2.60%

cases:5.76%

controls:2.38%

—

cases:5.60%

controls:2.74%

cases:18.00%

controls:7.59%

134

1349

131

1352

—

118

1313

1108

Essential (primary) hypertension
I10 [45591453]

4.1e-01

5.5e-01

9.9e-01

1.0e+50

1.2e+00

9.6e-01

4.9e-01

cases:23.02%

controls:16.53%

cases:13.67%

controls:8.38%

cases:3.60%

controls:1.37%

cases:7.19%

controls:0.00%

cases:5.04%

controls:1.52%

cases:20.00%

controls:8.74%

cases:36.00%

controls:25.69%

229

107

1156

116

120

1269

134

1366

129

1385

132

1362

118

100

1232

308

891

Senile nuclear cataract
H25.1 [45581628]

9.5e-01

—

6.0e-02

cases:12.95%

controls:5.42%

—

cases:6.00%

controls:5.67%

121

1310

—

1131

Pharmacy visit
OMOP4822462 [581458]

1.0e+00

6.8e-01

4.7e-01

9.6e-01

9.1e-01

9.2e-01

5.1e-01

cases:97.12%

controls:92.20%

cases:91.37%

controls:84.26%

cases:58.99%

controls:47.29%

cases:7.19%

controls:2.89%

cases:68.35%

controls:46.49%

cases:93.60%

controls:85.41%

cases:97.00%

controls:95.08%

135

1277

108

127

1167

218

655

730

129

1345

643

740

117

1153

197

1140

zopiclone; oral
N05CF01 [21604654]

7.8e-01

8.6e-01

—

7.1e-01

7.6e-01

cases:20.86%

controls:10.83%

cases:15.11%

controls:7.00%

—

cases:13.60%

controls:7.19%

cases:20.00%

controls:10.43%

150

110

1235

118

1288

—

108

1253

125

1074

Neurology
13 [38004458]

7.8e-01

7.2e-01

—

9.0e-01

7.4e-01

cases:20.86%

controls:10.83%

cases:9.35%

controls:4.77%

—

cases:10.40%

controls:4.52%

cases:25.00%

controls:13.76%

150

110

1235

126

1319

—

112

1289

165

1034

Ophthalmology
18 [38004463]

7.3e-01

5.3e-01

—

6.6e-01

7.0e-01

cases:29.50%

controls:16.82%

cases:12.95%

controls:8.01%

—

cases:12.80%

controls:7.04%

cases:32.00%

controls:18.93%

233

1152

111

121

1274

—

109

1255

227

972

misoprostol; oral
A02BB01 [21600093]

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

100

1192

Basic examination of mouth
SAA02 [2001310275]

3.6e-01

2.3e-01

—

1.7e-01

4.6e-01

cases:7.91%

controls:5.63%

cases:3.60%

controls:2.89%

—

cases:4.00%

controls:3.41%

cases:17.00%

controls:11.43%

128

1307

134

1345

—

120

1304

137

1062

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

7.5e-01

1.4e+00

—

1.0e+00

cases:3.60%

controls:1.73%

cases:5.04%

controls:1.30%

—

cases:12.00%

controls:4.67%

134

1361

132

1367

—

1143

Abdominal pain epigastric
D02 [2002000301]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:0.75%

139

1379

—

100

1190

Irregular heartbeat other
K05 [2002000548]

—

-1.0e+50

—

cases:0.00%

controls:0.50%

—

100

1193

timolol, combinations
S01ED51 [21603705]

6.8e-01

7.1e-01

—

cases:4.32%

controls:2.24%

cases:3.60%

controls:1.81%

—

133

1354

134

1360

—

pivmecillinam; oral
J01CA08 [21602827]

-6.2e-02

-2.4e-01

—

-1.0e+50

4.4e-01

2.0e-01

cases:7.91%

controls:8.38%

cases:3.60%

controls:4.55%

—

cases:0.00%

controls:0.36%

cases:6.40%

controls:4.22%

cases:13.00%

controls:10.93%

116

128

1269

134

1322

—

139

1378

117

1293

131

1068

calcium carbonate
A02AC01 [21600065]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Other seropositive rheumatoid arthritis
M05.8 [45538634]

1.7e+00

—

1.5e+00

cases:3.60%

controls:0.65%

—

cases:5.00%

controls:1.17%

134

1376

—

1185

Intramuscular and subcutaneous injection
SPAT1256 [2001700357]

-7.1e-02

1.5e-01

-1.0e+50

—

4.2e-01

cases:4.32%

controls:4.62%

cases:3.60%

controls:3.10%

cases:0.00%

controls:0.65%

cases:0.00%

controls:0.36%

—

cases:12.00%

controls:8.26%

133

1321

134

1342

139

1376

139

1380

—

1100

Puncture of vitreous body with injection of medication
CKD05 [2001301407]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

125

1338

—

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

9.3e-01

—

cases:7.19%

controls:2.96%

—

129

1344

—

Pain general/multiple sites
A01 [2002000142]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Counselling/guidance promoting independent living
SPAT1222 [2001700323]

—

3.7e-01

—

cases:5.00%

controls:3.50%

—

1157

Excision of skin or mucous membrane lesion
SPAT1141 [2001700242]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Pain localized to upper abdomen
R10.1 [45568111]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

125

1344

—

Screening procedure
SPAT1324 [2001700425]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]

-1.0e+50

—

cases:0.00%

controls:1.59%

—

139

1363

—

hydroxyzine; oral, parenteral
N05BB01 [21604590]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

139

1369

—

Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]

—

-1.0e+50

—

1.0e+00

—

cases:0.00%

controls:0.36%

—

cases:5.00%

controls:1.83%

—

139

1380

—

1177

Pain in joint
M25.5 [45586941]

7.5e-01

-1.0e+50

—

cases:3.60%

controls:1.73%

cases:0.00%

controls:0.51%

—

134

1361

139

1378

—

Limited function/disability (L)
L28 [2002000647]

—

1.5e+00

3.2e-01

—

cases:5.60%

controls:1.26%

cases:7.00%

controls:5.17%

—

118

1333

1137

ambroxol; oral
R05CB06 [21603385]

1.0e+00

—

cases:3.60%

controls:1.30%

—

134

1367

—

Geriatric Psychiatry
27 [38004470]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.51%

—

cases:0.00%

controls:0.50%

139

1378

—

100

1193

Respiratory and circulatory monitoring
WX700 [2001310817]

—

7.8e-01

—

cases:6.00%

controls:2.84%

—

1165

drospirenone and estetrol
G03AA18 [947983]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Acute bronchitis, unspecified
J20.9 [45562445]

9.3e-01

—

9.5e-01

cases:3.60%

controls:1.44%

—

cases:5.00%

controls:2.00%

134

1365

—

1175

Skin symptom/complaint other
S29 [2002000993]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.94%

—

cases:0.00%

controls:2.42%

—

139

1372

—

100

1170

etodolac; oral
M01AB08 [21603948]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:0.83%

—

139

1379

—

100

1189

Electrophysiological examination of eye
XCD10 [2001300413]

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

prednisolone; oral, parenteral
H02AB06 [21602734]

8.0e-01

9.4e-01

—

1.1e+00

7.6e-01

7.5e-01

cases:17.27%

controls:8.59%

cases:11.51%

controls:4.84%

—

cases:4.32%

controls:1.45%

cases:9.60%

controls:4.74%

cases:21.00%

controls:11.18%

119

115

1266

123

1318

—

133

1363

113

1286

134

1065

Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]

—

7.8e-01

—

cases:8.00%

controls:3.84%

—

1153

vildagliptin; oral
A10BH02 [21600785]

—

-1.0e+50

—

cases:0.00%

controls:0.92%

—

100

1188

hydrocortisone and antiinfectives
S02CA03 [21605175]

—

-1.0e+50

—

cases:0.00%

controls:1.42%

—

100

1182

Gonarthrosis [arthrosis of knee]
M17 [45601350]

—

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

combinations of corticosteroids
D07AB30 [21602118]

4.9e-01

9.1e-01

-1.0e+50

—

5.2e-01

cases:13.67%

controls:8.88%

cases:9.35%

controls:3.97%

cases:0.00%

controls:0.51%

—

cases:5.60%

controls:3.41%

cases:18.00%

controls:11.51%

123

120

1262

126

1330

139

1378

—

118

1304

138

1061

Hand Surgery
40 [38004480]

—

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

Insect bite/sting
S12 [2002000977]

—

-1.0e+50

—

cases:0.00%

controls:0.83%

—

100

1189

Skin texture symptom/complaint
S21 [2002000986]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.51%

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:1.50%

139

1378

139

1379

—

100

1181

Idiopathic gout
M10.0 [45577131]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]

-1.0e+50

—

cases:0.00%

controls:0.65%

—

139

1376

—

Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]

8.4e-01

3.9e-01

—

-1.0e+50

—

2.9e-01

cases:15.11%

controls:7.15%

cases:3.60%

controls:2.45%

—

cases:0.00%

controls:0.36%

—

cases:8.00%

controls:6.09%

118

1286

134

1351

—

139

1378

—

1126

Occupatioal Medicine
901 [44777713]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

felodipine; oral
C08CA02 [21601748]

2.9e-01

—

5.4e-01

9.5e-01

cases:4.32%

controls:3.25%

—

cases:4.00%

controls:2.37%

cases:7.00%

controls:2.84%

133

1340

—

120

1318

1165

Decubitus ulcer and pressure area
L89 [45601235]

—

-1.0e+50

—

cases:0.00%

controls:0.50%

—

100

1193

levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]

7.8e-01

—

7.2e-01

cases:4.32%

controls:2.02%

—

cases:6.00%

controls:3.00%

133

1357

—

1163

cefuroxime; oral, parenteral
J01DC02 [21602884]

—

-1.0e+50

—

cases:0.00%

controls:0.75%

—

100

1190

betamethasone
S02BA07 [21605169]

2.7e-02

—

cases:5.04%

controls:4.91%

—

132

1317

—

Dysuria
R30.0 [45592416]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Urine symptom/complaint other
U07 [2002001142]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.36%

—

cases:0.00%

controls:0.83%

139

1380

—

100

1189

Sicca syndrome [Sjögren]
M35.0 [45562711]

—

-1.0e+50

—

cases:0.00%

controls:0.50%

—

100

1193

Chest pain NOS
A11 [2002000152]

-1.0e+50

—

cases:0.00%

controls:0.65%

—

139

1376

—

zinc bandage without supplements
D09AB01 [21602278]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Dilated cardiomyopathy
I42.0 [45586581]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.36%

—

cases:0.00%

controls:0.44%

cases:0.00%

controls:1.00%

139

1380

—

125

1344

100

1187

Fall on same level involving ice and snow
W00 [45756242]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

125

1345

—

Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]

-1.0e+50

—

cases:0.00%

controls:1.37%

—

139

1366

—

Giving the first information
R2110 [2001310194]

-1.0e+50

—

cases:0.00%

controls:0.58%

—

139

1377

—

Gynaecological examination
SPAT1192 [2001700293]

—

-1.0e+50

—

cases:0.00%

controls:0.50%

—

100

1193

hydrocortisone butyrate
D07AB02 [21602106]

9.7e-02

8.4e-01

-1.0e+50

—

2.9e-02

cases:7.19%

controls:6.57%

cases:3.60%

controls:1.59%

cases:0.00%

controls:0.58%

—

cases:6.00%

controls:5.84%

129

1294

134

1363

139

1377

—

1129

One-surface restoration
SFA10 [2001310358]

5.6e-01

—

-1.0e+50

8.9e-01

4.3e-01

cases:7.91%

controls:4.69%

—

cases:0.00%

controls:0.43%

cases:5.60%

controls:2.37%

cases:15.00%

controls:10.26%

128

1320

—

139

1377

118

1318

123

1076

calcium carbonate; oral
A12AA04 [21600863]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

betamethasone
A07EA04 [21600656]

2.7e-02

—

cases:5.04%

controls:4.91%

—

132

1317

—

Refractory anaemia without ring sideroblasts, so stated
D46.0 [45571623]

—

1.0e+50

—

cases:3.60%

controls:0.00%

—

134

1385

—

Lipid disorder
T93 [2002001134]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

100

1191

Transurethral resection of bladder
KCD02 [2001305938]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

memantine; oral
N06DX01 [21604799]

-1.0e+50

—

-1.0e+50

—

3.8e-01

cases:0.00%

controls:1.30%

—

cases:0.00%

controls:0.80%

—

cases:6.00%

controls:4.17%

139

1367

—

139

1372

—

1149

boric acid
S02AA03 [21605149]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

100

1191

amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]

3.3e-01

7.5e-01

—

5.2e-01

cases:7.19%

controls:5.27%

cases:3.60%

controls:1.73%

—

cases:12.00%

controls:7.51%

129

1312

134

1361

—

1109

Application of soft bandage
SPAT1211 [2001700312]

—

-1.0e+50

—

cases:0.00%

controls:1.83%

—

100

1177

prednisolone
S03BA02 [21605202]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

cases:0.00%

controls:1.83%

—

139

1380

—

100

1177

Reticulocytes [#/volume] in Blood
14196-0 [3023520]

—

1.8e+00

—

cases:6.00%

controls:1.00%

—

1187

Extensive health certificate
SPAT1284 [2001700385]

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

100

1192

SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]

1.1e-01

—

cases:3.60%

controls:3.25%

—

134

1340

—

Flexible bronchoscopy
UGC12 [2001303610]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

125

1345

—

Chronic apical periodontitis
K04.5 [45586691]

7.9e-01

-1.0e+50

—

cases:3.60%

controls:1.66%

cases:0.00%

controls:0.79%

—

134

1362

139

1374

—

travoprost
S01EE04 [21603713]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.51%

—

cases:0.00%

controls:0.75%

139

1378

—

100

1190

methylprednisolone; oral, parenteral
H02AB04 [21602732]

1.2e+00

—

cases:5.04%

controls:1.52%

—

132

1364

—

hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]

6.0e-01

7.7e-01

-1.0e+50

—

cases:9.35%

controls:5.34%

cases:6.47%

controls:3.10%

cases:0.00%

controls:0.87%

—

126

1311

130

1342

139

1373

—

Rectocele
N81.6 [45543893]

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

Basocellular carcinoma of the skin of the scalp and neck
C44.41 [2000500796]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Actinic keratosis
L57.0 [45591640]

—

-1.0e+50

—

cases:0.00%

controls:0.74%

—

125

1340

—

alfuzosin; oral
G04CA01 [21602668]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

cases:0.00%

controls:2.34%

—

139

1375

—

100

1171

Supraventricular tachycardia
I47.1 [45567178]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

furosemide and potassium-sparing agents
C03EB01 [21601554]

1.1e+00

—

cases:5.04%

controls:1.81%

—

132

1360

—

Base excess in Arterial blood by calculation
1925-7 [3003396]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]

3.1e-01

3.5e-01

-1.0e+50

—

3.0e-01

1.1e-01

cases:28.06%

controls:22.24%

cases:12.95%

controls:9.53%

cases:0.00%

controls:1.23%

—

cases:12.80%

controls:9.78%

cases:25.00%

controls:22.94%

308

100

1077

132

121

1253

139

1368

—

132

109

1218

275

924

tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

139

1377

—

norethisterone and ethinylestradiol
G03AA05 [21602478]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

139

1373

—

Open wound of wrist and hand, part unspecified
S61.9 [45554740]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

amiodarone; oral, parenteral
C01BD01 [21600270]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Teeth/gum disease
D82 [2002000380]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.30%

—

cases:0.00%

controls:1.41%

—

139

1367

—

125

1331

—

Knee symptom/complaint
L15 [2002000639]

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

139

1377

—

Operation for osteochondritis of knee, arthroscopic
NGF25 [2001308133]

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

125

1344

—

Basocellular carcinoma of the skin on the torso
C44.51 [2000500800]

—

-1.0e+50

—

cases:0.00%

controls:0.50%

—

100

1193

latanoprost
S01EE01 [21603710]

5.8e-01

—

-1.0e+50

—

-1.0e+50

—

cases:4.32%

controls:2.45%

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.72%

—

133

1351

—

139

1374

—

139

1373

—

Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]

—

1.3e+00

—

8.4e-01

—

cases:5.04%

controls:1.44%

—

cases:10.00%

controls:4.59%

—

132

1365

—

1144

Sytologyspecimen from mouth of uterus
XLD00 [2001306651]

-1.0e+50

—

cases:0.00%

controls:0.94%

—

139

1372

—

chloramphenicol
G01AA05 [21602367]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

139

1374

—

lamotrigine; oral
N03AX09 [21604431]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

cases:0.00%

controls:0.50%

—

139

1380

—

100

1193

dexamethasone; oral, parenteral
H02AB02 [21602730]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

cases:0.00%

controls:0.36%

—

139

1364

—

139

1378

—

Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]

1.6e-01

3.1e-01

2.0e+00

—

6.2e-02

4.0e-03

cases:10.79%

controls:9.31%

cases:9.35%

controls:7.00%

cases:3.60%

controls:0.51%

—

cases:8.00%

controls:7.56%

cases:21.00%

controls:20.93%

129

124

1256

126

1288

134

1378

—

102

115

1248

251

948

ramipril; oral
C09AA05 [21601789]

5.1e-01

8.2e-02

—

-3.7e-01

6.9e-02

cases:11.51%

controls:7.22%

cases:6.47%

controls:5.99%

—

cases:4.80%

controls:6.81%

cases:11.00%

controls:10.34%

100

123

1285

130

1302

—

119

1258

124

1075

Hypertensive heart disease without (congestive) heart failure
I11.9 [45576863]

1.5e+00

—

cases:3.60%

controls:0.79%

—

134

1374

—

Alzheimer disease, unspecified
G30.9 [45591165]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

125

1344

—

Adjustment and management of cardiac devices
Z45.0 [45595515]

2.1e+00

—

cases:3.60%

controls:0.43%

—

134

1379

—

Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Dental caries
K02 [45552906]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

100

1191

Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

139

1374

—

Malaise and fatigue
R53 [45553741]

5.6e-01

—

1.0e+00

5.6e-01

cases:3.60%

controls:2.09%

—

cases:4.00%

controls:1.48%

cases:9.00%

controls:5.34%

134

1356

—

120

1330

1135

Subcutaneous
ZX112 [2001311492]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Split tooth for reasons other than trauma
K03.82 [2000502700]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:1.25%

—

139

1379

—

100

1184

Urinary frequency/urgency
U02 [2002001138]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

139

1371

—

Memory disturbance
P20 [2002000816]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:0.36%

—

139

1379

—

139

1378

—

Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]

—

1.9e+00

—

cases:5.00%

controls:0.75%

—

1190

captopril; oral
C09AA01 [21601785]

-1.0e+50

—

cases:0.00%

controls:0.58%

—

139

1377

—

Separate instruction to prepare for procedure
SPAT1266 [2001700367]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

dexamethasone
D10AA03 [21602286]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

139

1374

—

Spinal stenosis
M48.0 [45557888]

4.6e-01

—

cases:3.60%

controls:2.31%

—

134

1353

—

Periodontitis complex
K05.30 [2000502728]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.58%

—

cases:0.00%

controls:1.50%

139

1377

—

100

1181

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

-1.3e-01

4.0e-01

1.4e+00

—

-1.0e+50

-1.6e-01

1.4e-02

cases:8.63%

controls:9.68%

cases:10.79%

controls:7.51%

cases:3.60%

controls:0.87%

—

cases:0.00%

controls:0.36%

cases:7.20%

controls:8.37%

cases:21.00%

controls:20.77%

134

127

1251

104

124

1281

134

1373

—

139

1378

113

116

1237

249

950

pH of Specimen
17433-4 [3019225]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.94%

—

cases:0.00%

controls:0.44%

cases:0.00%

controls:1.67%

139

1372

—

125

1344

100

1179

ezetimibe; oral
C10AX09 [21601896]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

cases:0.00%

controls:0.72%

—

cases:0.00%

controls:0.59%

—

139

1374

139

1375

—

125

1342

—

Physical Medicine And Rehabilitation
25 [38004468]

7.1e-01

—

7.5e-01

4.8e-01

cases:10.07%

controls:5.20%

—

cases:4.00%

controls:1.93%

cases:10.00%

controls:6.42%

125

1313

—

120

1324

1122

Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

125

1344

—

Other senile cataract
H25.8 [45605644]

9.8e-01

—

cases:5.04%

controls:1.95%

—

132

1358

—

Excision of redundant skin of eyelid
CBB10 [2001300923]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Myelocytes/Leukocytes in Blood
26498-6 [3017181]

-1.0e+50

—

2.1e+00

cases:0.00%

controls:0.43%

—

cases:5.00%

controls:0.67%

139

1379

—

1191

Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.08%

cases:0.00%

controls:1.01%

—

cases:0.00%

controls:0.89%

—

139

1370

139

1371

—

125

1338

—

Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

FEV1/FVC
19926-5 [3011505]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

139

1375

—

amitriptyline; oral, parenteral
N06AA09 [21604696]

1.1e+00

—

7.8e-01

cases:6.47%

controls:2.31%

—

cases:6.00%

controls:2.84%

130

1353

—

1165

Body temperature
8310-5 [3020891]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

—

100

1194

Cardiac arrhythmia NOS
K80 [2002000607]

-1.0e+50

—

cases:0.00%

controls:0.43%

—

139

1379

—

valsartan; oral
C09CA03 [21601826]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.65%

—

cases:0.00%

controls:0.59%

—

139

1376

—

125

1342

—

Adhesive capsulitis of shoulder
M75.0 [45533931]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:0.83%

139

1379

—

100

1189

Upper respiratory infection acute
R74 [2002000942]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:0.52%

cases:0.00%

controls:3.09%

—

139

1379

—

125

1343

100

1162

SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Spinalanesthesia
WX320 [2001310799]

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

139

1377

—

Radiological examination, not elsewhere classified
Z01.6 [45605096]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.72%

—

cases:0.00%

controls:0.67%

139

1375

—

100

1191

Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]

-1.0e+50

—

cases:0.00%

controls:0.51%

—

139

1378

—

venlafaxine; oral
N06AX16 [21604745]

9.9e-01

—

cases:3.60%

controls:1.37%

—

134

1366

—

losartan; oral
C09CA01 [21601824]

2.6e-01

3.2e-02

—

5.3e-01

5.1e-01

cases:6.47%

controls:5.05%

cases:4.32%

controls:4.19%

—

cases:7.20%

controls:4.37%

cases:11.00%

controls:6.92%

130

1315

133

1327

—

116

1291

1116

Ear symptom/complaint other
H29 [2002000484]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

Bilateral
ZXA10 [2001311348]

8.9e-01

—

cases:5.76%

controls:2.45%

—

131

1351

—

fluocortolone
D07AC05 [21602124]

-1.0e+50

—

cases:0.00%

controls:0.72%

cases:0.00%

controls:0.43%

—

139

1375

139

1379

—

Carpal tunnel syndrome
G56.0 [45566891]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.43%

—

cases:0.00%

controls:1.33%

—

139

1379

—

100

1183

Cerebral infarction due to embolism of cerebral arteries
I63.4 [45591475]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.36%

—

cases:0.00%

controls:0.83%

139

1380

—

100

1189

Pleural plaque with presence of asbestos
J92.0 [45567277]

-1.0e+50

—

cases:0.00%

controls:0.43%

—

139

1379

—

Other otitis externa
H60.8 [45567109]

-1.0e+50

—

cases:0.00%

controls:0.36%

—

139

1380

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3022948) Iron [Moles/volume] in Serum or Plasma

179

4.27

14.87

5.9

2.1

12.78

12.87

umol/l

0.02

162

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

156

3.89

11.97

6.2

2.1

23.25

21.56

0.23

145

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

5.01

8.68

3.2

2.8

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

7.83

6.08

1.5

2.1

—

(3020630) Protein [Mass/volume] in Serum or Plasma

3.28

5.80

2.9

2.5

66.57

65.49

g/l

0.30

(3044640) Blood type and Crossmatch panel - Blood

331

2.28

5.19

13.2

2.6

—

(21494434) Karyotype in Bone marrow

14.02

5.14

1.5

1.0

—

(3045142) Bone marrow Pathology biopsy report

10.58

5.10

1.4

1.0

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

122

2.73

4.97

6.2

4.0

253.00

239.30

u/l

0.13

115

(3020779) Urea [Moles/volume] in Serum or Plasma

2.96

4.77

7.3

5.3

9.20

11.23

mmol/l

0.57

(1761482) Bacteria [#/volume] in Urine by Culture

3.70

4.61

4.4

5.5

—

(3019150) Specific gravity of Urine by Refractometry

251

2.24

4.48

6.7

4.7

1.02

kg/l

1.79

167

(3042111) Morphology [Interpretation] in Bone marrow Narrative

6.63

4.38

1.3

—

(3012544) pH of Venous blood

124

2.57

4.32

4.8

3.3

7.40

7.38

1.76

(3000330) Specific gravity of Urine by Test strip

2.98

4.11

4.9

4.3

1.01

1.02

ratio

1.36

(3023520) Reticulocytes [#/volume] in Blood

108

2.60

4.04

6.0

1.8

58.27

64.92

e9/l

0.42

(43055120) Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

7.63

3.91

1.4

1.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

257

2.10

3.84

6.7

4.0

0.00

0.29

—

(3035637) Corticotropin [Mass/volume] in Plasma

7.29

3.40

1.6

23.71

53.40

ng/l

—

(3030366) Cystatin C [Mass/volume] in Serum or Plasma

3.89

3.16

4.9

1.9

1.41

1.75

mg/l

0.75

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.56

3.15

2.1

1.5

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

4.50

3.05

14.8

1.8

3.72

3.90

g/l

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

3.01

2.8

1.5

2.79

2.85

g/l

0.10

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

10.30

3.00

1.4

3.6

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.55

2.85

2.3

2.5

—

(3019309) Folate [Moles/volume] in Red Blood Cells

227

1.92

2.78

1.7

1132.25

1188.08

nmol/l

0.17

170

(3023465) Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis

3.18

2.77

2.5

1.5

10.08

8.99

g/l

0.45

(21494815) CD4 cells/Lymphocytes in Specimen

8.58

2.77

1.2

2.5

47.44

38.27

—

(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

2.82

2.71

2.8

1.5

7.55

7.52

g/l

0.02

(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

2.82

2.71

2.8

1.5

3.77

3.32

g/l

0.63

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

2.82

2.71

2.8

1.5

4.40

4.36

g/l

0.04

(3014051) Protein [Presence] in Urine by Test strip

296

1.82

2.67

6.5

3.5

0.00

0.18

0.47

(3001604) Monocytes [#/volume] in Blood

516

1.71

2.51

16.5

5.1

0.61

0.60

e9/l

0.13

445

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

461

1.71

2.49

10.8

2.9

—

estimate

—

(3006315) Basophils [#/volume] in Blood

517

1.70

2.48

16.5

5.1

0.04

e9/l

0.31

445

(42870588) Differential panel, method unspecified - Blood

330

1.74

2.41

15.7

4.4

—

(3000991) Gas panel - Venous blood

2.23

2.40

6.7

8.9

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

6.43

2.39

1.0

1.4

—

(3005719) IgG [Mass/volume] in Serum or Plasma

2.42

2.34

4.3

2.5

10.33

10.18

g/l

0.04

(3051014) Leukocytes [#/area] in Urine sediment by Automated count

4.77

2.29

2.0

2.2

—

3.67

—

(3013115) Eosinophils [#/volume] in Blood

536

1.65

2.25

18.1

5.2

0.17

0.20

e9/l

0.88

473

(3019198) Lymphocytes [#/volume] in Blood

527

1.65

2.24

16.5

5.2

1.89

1.90

e9/l

0.03

473

(3045788) Cell count panel - Pleural fluid

5.71

2.23

1.4

1.1

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

408

1.67

2.22

3.7

3.3

1777.07

1659.46

ng/l

0.09

351

(3007853) Bacteria identified in Skin by Aerobe culture

120

1.99

2.07

1.6

1.8

—

(3037522) Nuclear Ab [Titer] in Serum

115

1.97

1.96

1.3

251.43

418.67

titre

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

252

1.70

1.93

2.3

1.8

360.79

474.89

pmol/l

2.59

209

(3007628) Bicarbonate [Moles/volume] standard in Venous blood

2.24

1.89

3.3

3.6

23.46

23.89

mmol/l

0.11

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

1.74

0.0

1.8

—

(46236952) Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M

2.01

1.74

3.1

3.4

57.33

59.41

ml/min/173m2

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

563

1.53

1.68

9.6

6.8

1.23

1.21

mmol/l

0.64

494

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.17

1.65

1.2

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

2.78

1.60

1.1

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

3.09

1.60

1.5

1.6

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

3.09

1.60

1.5

1.6

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

0.00

1.53

0.0

1.6

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

168

1.67

1.45

8.3

1.6

30.40

29.35

0.39

163

(3015736) pH of Urine

452

1.48

1.44

6.4

3.8

6.63

6.27

1.48

250

(40760892) CBC W Ordered Manual Differential panel - Blood

211

1.60

1.41

7.2

5.2

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

3.01

1.37

2.6

1.8

—

(3024928) Oxygen saturation in Venous blood

2.56

1.32

1.0

2.5

65.13

57.16

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

2.56

1.32

1.7

1.1

—

(40761511) CBC panel - Blood by Automated count

998

0.69

1.31

31.4

14.9

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

321

1.49

1.30

3.8

2.8

27.93

30.20

u/l

0.41

303

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

2.12

1.29

1.6

1.2

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

585

1.43

1.28

22.4

8.4

4.35

4.24

e9/l

0.10

513

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

2.46

1.25

1.2

—

(42529406) Shigella sp [Presence] in Stool by Culture

2.46

1.25

1.2

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

2.46

1.25

1.2

—

(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma

129

0.44

1.23

2.8

5.2

43.17

32.25

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

2.55

1.16

1.0

1.2

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

179

1.55

1.13

4.8

3.0

1.17

1.18

e6/l

0.01

100

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

2.32

1.12

1.0

1.3

—

(3007164) IgA [Mass/volume] in Serum or Plasma

189

1.53

1.10

1.4

1.3

2.91

2.59

g/l

0.38

102

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

304

0.64

1.09

4.6

4.9

23.65

21.56

0.34

155

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

174

1.53

1.04

5.0

3.2

3.00

2.21

e6/l

0.21

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

236

1.46

1.02

17.1

2.5

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

1.99

0.98

1.1

1.4

—

(3000475) Leukocytes [#/volume] in Synovial fluid

2.19

0.92

2.3

1.3

8145.33

6264.00

e6/l

—

(3018418) pH of Serum or Plasma

334

1.37

0.88

8.8

3.8

7.38

7.40

0.82

238

(3006184) Hemoglobin [Mass/volume] in Capillary blood

1.91

0.83

1.7

2.1

110.00

123.10

g/l

—

(3021589) Normoblasts [#/volume] in Blood

442

1.32

0.81

25.6

10.6

0.00

0.01

e9/l

0.29

355

(3026493) Urate [Moles/volume] in Serum or Plasma

284

1.36

0.79

4.4

2.8

361.69

354.70

umol/l

0.15

237

(3035350) Ketones [Presence] in Urine by Test strip

579

1.30

0.79

7.6

4.2

0.00

estimate

-0.00

120

(3033658) Prothrombin time (PT) actual/Normal

257

1.37

0.78

11.8

3.8

84.52

85.53

0.08

251

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

1.80

0.77

1.8

2.4

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

2.22

0.77

1.0

1.2

—

(3003327) Ova and parasites identified in Stool by Light microscopy

2.12

0.75

3.4

1.5

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

2.04

0.73

1.6

1.5

—

(3025941) Bacteria identified in Stool by Culture

1.62

0.73

1.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

136

1.46

0.71

2.1

1.7

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

1.96

0.71

1.0

1.2

—

(3016921) Smith extractable nuclear Ab [Units/volume] in Serum

1.96

0.71

1.0

1.3

—

2.28

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

1.88

0.69

1.0

1.1

—

(3006999) Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum

1.88

0.69

1.0

1.3

—

2.08

—

(1761868) Lipid panel - Serum or Plasma

310

0.73

0.68

3.0

3.7

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

385

1.29

0.67

7.2

3.3

—

(40768797) Stomach Pathology biopsy report

139

1.42

0.64

1.8

1.2

—

(3009261) Glucose [Presence] in Urine by Test strip

582

1.25

0.62

7.8

4.3

0.00

estimate

-0.00

111

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

1.69

0.62

1.0

1.1

—

(3021601) Nitrite [Presence] in Urine by Test strip

573

1.25

0.61

7.8

4.2

0.00

estimate

-0.00

115

(3045716) Anion gap in Serum or Plasma by calculation

0.00

0.60

0.0

2.4

—

10.19

—

(40768800) Prostate Pathology biopsy report

0.00

0.60

0.0

1.2

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

504

0.79

0.60

2.6

2.7

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.53

0.59

1.9

1.4

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

497

1.25

0.59

2.8

2.1

89.81

96.72

pmol/l

0.62

247

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

441

1.25

0.56

8.4

4.3

0.00

0.03

estimate

0.49

(3034780) Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma

1.65

0.56

1.0

2.4

55.33

43.02

u/l

—

(3026008) Bacteria identified in Urine by Culture

365

1.26

0.56

5.3

3.6

—

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

254

1.28

0.53

2.5

2.9

2.44

2.47

mmol/l

0.61

231

(40768804) Tissue Pathology biopsy report

404

0.79

0.53

2.2

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

172

1.33

0.52

1.2

1.3

47.99

41.49

iu/ml

—

(3002582) Erythrocytes [#/volume] in Urine

371

1.23

0.48

6.4

3.4

18.25

57.98

e6/l

1.95

283

(3002256) Pathology report gross observation

128

0.68

0.46

1.0

1.3

—

(3020682) Albumin/Creatinine [Ratio] in Urine

367

1.21

0.41

6.0

4.1

13.84

13.37

mg/mmol

0.03

229

(3003191) Choriogonadotropin [Presence] in Serum or Plasma

0.00

0.41

0.0

1.8

—

(1002224) Polysomnography panel

1.49

0.41

1.0

1.2

—

(3042936) Bacteria identified in Isolate by Culture

161

1.28

0.40

2.0

1.7

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.64

0.37

2.2

1.7

—

(3018095) Leukocytes [#/volume] in Urine

412

1.17

0.34

7.6

4.1

10.90

114.33

e6/l

3.02

291

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

0.71

0.32

1.0

1.3

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.31

0.31

2.3

1.7

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

214

1.20

0.30

1.2

1.4

1.20

2.31

u/ml

—

(3023368) Bacteria identified in Blood by Culture

348

1.17

0.30

6.5

3.9

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.26

0.30

1.7

1.3

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.31

0.28

1.5

1.6

—

(3000494) Fungus identified in Specimen by Culture

123

1.25

0.26

1.4

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

1.21

0.25

2.3

1.7

—

(3016502) Oxygen saturation in Arterial blood

134

1.22

0.24

5.9

6.7

96.19

94.75

0.57

129

(4035726) Immunohistochemistry procedure

1.27

0.23

1.5

1.3

—

(3003694) ABO and Rh group [Type] in Blood

259

1.15

0.22

1.6

1.4

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

145

1.20

0.22

2.2

1.6

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

1.20

0.21

1.0

1.1

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.0

—

(40759850) Jo-1 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

0.21

0.0

1.4

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

0.21

0.0

1.4

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.0

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.0

—

(3000242) Tau protein [Mass/volume] in Cerebral spinal fluid

0.00

0.21

0.0

1.0

—

281.40

—

(40759836) Histone Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(4281824) Cell count and differential, peritoneal fluid

0.00

0.21

0.0

1.0

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

0.00

0.21

0.0

1.4

—

(43055225) Phosphorylated tau 181 [Mass/volume] in Cerebral spinal fluid by Immunoassay

0.00

0.21

0.0

1.1

—

38.40

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.21

0.0

1.1

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

0.00

0.21

0.0

1.4

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(3042810) Amyloid beta 42 peptide [Mass/volume] in Cerebral spinal fluid

0.00

0.21

0.0

1.0

—

432.20

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.21

0.0

1.1

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

0.00

0.21

0.0

1.4

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

0.21

0.0

1.9

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.8

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.7

—

(3017569) Oxygen content in Arterial blood

0.00

0.21

0.0

1.8

—

15.94

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.21

0.0

1.5

—

(3016888) Borrelia burgdorferi IgG Ab [Units/volume] in Serum

1.26

0.20

1.5

1.3

—

33.90

—

(3046279) Procalcitonin [Mass/volume] in Serum or Plasma

1.26

0.20

2.0

1.5

0.20

1.39

ug/l

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.20

0.0

1.6

—

0.95

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.20

0.0

1.6

—

0.88

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.20

0.0

1.6

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.20

0.0

1.8

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.20

0.0

1.6

—

8.49

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.20

0.0

1.3

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.20

0.0

1.6

—

0.88

—

(3019977) pH of Arterial blood

147

1.18

0.19

5.9

6.5

7.41

0.02

(3012516) Albumin [Mass/volume] in Urine

353

1.10

0.16

5.3

3.3

95.92

77.23

mg/l

0.17

233

(36660697) Celiac disease serology panel - Serum

0.77

0.16

1.0

1.2

—

(3027801) Oxygen [Partial pressure] in Arterial blood

150

1.15

0.15

5.9

6.3

12.45

11.79

kpa

0.23

143

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

150

1.15

0.15

5.9

6.2

5.05

5.08

kpa

0.05

141

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

473

1.09

0.15

6.1

4.4

56.16

55.64

ng/l

0.01

374

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

1.09

0.09

1.2

1.1

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.07

0.09

1.2

2.0

—

(40758558) Short blood count panel - Blood

322

1.07

0.09

21.3

5.9

—

(40768443) Skin Pathology biopsy report

1.14

0.09

1.3

1.2

—

(3020891) Body temperature

1.12

0.09

12.2

3.6

36.72

36.88

°c

—

(3000492) Spirometry study

1.06

0.08

1.3

1.7

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

108

1.12

0.07

2.1

1.5

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

1.08

0.07

8.6

5.4

26.32

24.37

mmol/l

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

737

0.95

0.07

5.8

4.3

15.26

15.04

pmol/l

0.30

649

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

236

1.07

0.07

4.4

3.9

518.95

288.72

ng/l

0.34

195

(3041096) Erythrocytes [Presence] in Urine by Automated

329

1.04

0.04

5.8

3.6

0.00

estimate

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

129

0.92

0.04

13.6

8.7

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

198

0.95

0.02

2.2

1.7

—

(3029937) Albumin [Presence] in Urine by Test strip

328

0.97

0.02

6.5

4.1

0.00

0.02

estimate

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

114

1.06

0.01

1.6

1.7

—

(3022145) Colonoscopy Study observation

101

0.99

0.00

1.2

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

129

1.01

0.00

1.8

1.6

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

123

0.97

0.00

4.8

3.0

—

(3013512) EKG study

383

0.99

0.00

7.3

4.1

—

(3000850) Epithelial cells [#/volume] in Urine

258

1.01

0.00

5.3

2.6

5.30

4.20

e6/l

0.15

231

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

112

0.98

0.00

1.5

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

155

1.04

0.00

1.1

1.3

33.39

11.68

u/ml

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.89

0.00

1.8

1.3

—

(3039355) Methicillin resistant Staphylococcus aureus [Presence] in Nose by Organism specific culture

0.00

-0.00

0.0

1.8

—

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

0.93

-0.00

2.4

3.3

5.10

5.14

kpa

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.3

—

(3024666) Lithium [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

10.6

—

0.72

—

(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma

0.98

-0.00

1.6

2.8

4.16

4.54

pmol/l

—

(3018333) Ribosomal P Ab [Presence] in Serum

0.00

-0.00

0.0

1.3

—

(3009991) Angiotensin converting enzyme [Enzymatic activity/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.2

—

1.32

—

(3038297) Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3019060) Gas panel - Arterial blood

0.92

-0.00

5.6

3.4

—

(3000208) Alpha tocopherol [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

32.40

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

-0.00

0.0

1.0

—

(3005082) Progesterone [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

33.30

—

(3025634) Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

-0.00

0.0

1.4

—

(3023410) Appearance of Cerebral spinal fluid

0.00

-0.00

0.0

1.3

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

-0.00

0.0

1.6

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.92

-0.00

1.2

2.1

—

(40760543) Extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.2

—

(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

10.82

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

0.00

-0.00

0.0

1.3

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

-0.00

0.0

2.1

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.3

—

(37208534) Antinuclear antibody arbitrary concentration in serum

0.00

-0.00

0.0

1.0

—

(37020445) Astrovirus RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(37020957) Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.1

—

(3042975) Streptococcus sp identified in Isolate by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3039429) Cortisol [Moles/volume] in Saliva (oral fluid)

0.00

-0.00

0.0

2.4

—

32.71

—

(4146454) Self-monitoring of blood glucose

0.00

-0.00

0.0

2.5

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.3

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

-0.00

0.0

1.0

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

0.00

-0.00

0.0

3.1

—

0.43

—

(3050898) Methicillin resistant Staphylococcus aureus [Presence] in Genital specimen by Organism specific culture

0.00

-0.00

0.0

2.4

—

(36306090) Helicobacter pylori [Presence] in Tissue by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3006262) Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3009306) Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

3.98

—

(46235760) Methicillin resistant Staphylococcus aureus [Presence] in Pharynx by Organism specific culture

0.00

-0.00

0.0

1.8

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.4

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.3

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

0.00

-0.00

0.0

1.0

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3030136) 5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

3.0

—

155.00

—

(3004451) EKG impression Narrative

0.00

-0.00

0.0

1.4

—

(3009595) Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.4

—

(3012158) Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3022689) Creatine [Moles/volume] in Urine

0.00

-0.00

0.0

1.4

—

7.76

—

(3042631) Mycobacterium sp identified in Specimen

0.00

-0.00

0.0

1.7

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

0.99

-0.00

3.0

3.8

1.19

1.22

mmol/l

—

(37021247) Adenovirus 40+41 DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(42869457) Rotavirus RNA [Identifier] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.1

—

Mortality – FinRegistry

↥

Association

Association between endpoint D3_SIDEROANAEMIAHERED and mortality.

Females

Parameter	HR [95% CI]	p-value
D3_SIDEROANAEMIAHERED	2.507 [1.96, 3.21]	< 0.001
Birth year	0.997 [0.99, 1.01]	0.451

During the follow-up period (1.1.1998 — 31.12.2019), 458 out of 704 females with D3_SIDEROANAEMIAHERED died.

Males

Parameter	HR [95% CI]	p-value
D3_SIDEROANAEMIAHERED	3.112 [2.13, 4.54]	< 0.001
Birth year	0.981 [0.97, 0.99]	< 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 380 out of 549 males with D3_SIDEROANAEMIAHERED died.

Mortality risk

Mortality risk for people of age

years, who have D3_SIDEROANAEMIAHERED.

N-year risk	Females	Males
1	0.255%	0.493%
5	1.629%	2.828%
10	3.978%	6.662%
15	7.385%	12.715%
20	12.639%	21.601%

Relationships between endpoints

↥

Index endpoint: D3_SIDEROANAEMIAHERED – Hereditary sideroblastic anaemia

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Hereditary sideroblastic anaemia

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints